Welcome to our dedicated page for Bioxcel Therapeutics news (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on Bioxcel Therapeutics stock.
BioXcel Therapeutics, Inc. (BTAI) is a clinical-stage biopharmaceutical company pioneering AI-driven drug re-innovation in neuroscience and immuno-oncology. This page serves as the definitive source for official updates including clinical trial progress, regulatory milestones, and strategic initiatives.
Investors and industry observers will find curated press releases detailing advancements in BXCL501 development for neuropsychiatric conditions, immuno-oncology research through subsidiary OnkosXcel, and financial disclosures. Our news collection enables stakeholders to track how machine learning accelerates therapeutic discovery while managing development risks.
Content is organized to highlight essential updates: clinical trial results, regulatory filings, research collaborations, and financial performance. Each update reflects BioXcel's unique approach combining big data analytics with established clinical science to address unmet medical needs.
Bookmark this page for direct access to verified information about BioXcel's innovative pipeline and corporate developments. Check regularly for updates on how artificial intelligence continues to reshape therapeutic discovery in high-need medical specialties.
BioXcel Therapeutics (Nasdaq: BTAI) announced its Q1 2023 financial results will be released on May 8, 2023, before U.S. markets open. The company will host a conference call at 8:00 AM ET to discuss the results and provide a business update. BioXcel specializes in using artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology. Their flagship product, IGALMI™, is a sublingual film approved for treating agitation associated with schizophrenia and bipolar disorders. The company is also evaluating several pipeline candidates for various indications. The press release includes forward-looking statements about anticipated outcomes and risks associated with the company’s operations.
On March 14, 2023, OnkosXcel Therapeutics announced the confidential submission of a draft registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock. The number of shares and price range of the offering have yet to be determined, with the IPO anticipated to follow the SEC's review, contingent on market conditions. OnkosXcel operates as a subsidiary of BioXcel Therapeutics (Nasdaq: BTAI). This announcement complies with Rule 135 of the Securities Act of 1933, and does not constitute an offer to sell or solicit offers to buy any securities.
BioXcel Therapeutics (BTAI) reported its 2022 financial results, revealing a net revenue of approximately $238,000 for Q4 and $375,000 for the full year, attributed to limited market access. The company's net loss for Q4 was $54.8 million, with a full-year loss of $165.8 million. IGALMI™ (dexmedetomidine) is now commercially launched, with strong interest in market access and an expanded field team of 70 representatives. Upcoming pivotal data readouts for BXCL501 are expected in Q2 2023, targeting significant agitation episodes. Strategic options for OnkosXcel are under exploration, while a conference call is planned for updates.
FAQ
What is the current stock price of Bioxcel Therapeutics (BTAI)?
What is the market cap of Bioxcel Therapeutics (BTAI)?
